AZN vs KZIA

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

KZIA presents a classic high-risk, high-reward biotechnology profile, anchored by a stable Piotroski F-Score of 4/9 and a lack of traditional valuation metrics like the Graham Number due to negative earnings. While the company exhibits explosive revenue growth (312.40% YoY) and maintains a clean balance sheet with zero debt and strong liquidity (Current Ratio 2.87), it is plagued by extreme operating losses and an unsustainable Price/Sales ratio of 53.08. The stark contrast between the bearish technical trend (0/100) and the aggressive analyst target price of $19.17 suggests a speculative environment driven by clinical expectations rather than current fundamentals.